SCM
RGLS

Sigma Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Sigma Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,956
Closed -$2.21M – 231
2013
Q3 		$2.21M Buy
+1,956
New +$2.31M 0.09% 199

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sigma Capital Management's RGLS Position: Q4 2013 in Review

Sigma Capital Management sold out of Regulus Therapeutics (RGLS) in Q4 2013, closing a stake of 1,956 shares — an estimated $2.21M sold.

Sigma Capital Management first reported a position in RGLS in Q3 2013 and held it in 1 quarter. The position peaked at $2.21M in Q3 2013. 49 funds tracked by Wall St. Rank hold RGLS as of Q4 2013.

  • Sigma Capital Management reported no remaining Regulus Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Sigma Capital Management sold 1,956 Regulus Therapeutics shares in Q4 2013, an estimated $2.21M.
  • Sigma Capital Management first reported a position in Regulus Therapeutics in Q3 2013 and held it in 1 quarter.
  • Sigma Capital Management's Regulus Therapeutics position peaked at $2.21M in Q3 2013.
  • 49 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2013.

Based on Sigma Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.